Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management
about
Diffuse panbronchiolitis and cystic fibrosis: East meets WestViral infections: a role in the lung disease of cystic fibrosis?A non-classical LysR-type transcriptional regulator PA2206 is required for an effective oxidative stress response in Pseudomonas aeruginosaExacerbations in cystic fibrosis: 2 . prevention.Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions.Epidemic spread of Pandoraea apista, a new pathogen causing severe lung disease in cystic fibrosis patients.Identification of peptides derived from the human antimicrobial peptide LL-37 active against biofilms formed by Pseudomonas aeruginosa using a library of truncated fragments.Elevated expression of both mRNA and protein levels of IL-17A in sputum of stable Cystic Fibrosis patients.Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.Anti-Pseudomonas aeruginosa antibody detection in patients with bronchiectasis without cystic fibrosis.Phenotypic characterization of clonal and nonclonal Pseudomonas aeruginosa strains isolated from lungs of adults with cystic fibrosis.Inhibition of high-mobility group box 1 protein (HMGB1) enhances bacterial clearance and protects against Pseudomonas Aeruginosa pneumonia in cystic fibrosis.alpha1-Antitrypsin Portland, a bioengineered serpin highly selective for furin: application as an antipathogenic agent.Production of elastase, exotoxin A, and alkaline protease in sputa during pulmonary exacerbation of cystic fibrosis in patients chronically infected by Pseudomonas aeruginosa.High Mobility Group Box-1 mediates hyperoxia-induced impairment of Pseudomonas aeruginosa clearance and inflammatory lung injury in mice.Induction of tumor necrosis factor (TNF) and interleukin-1 (IL-1) by Pseudomonas aeruginosa and exotoxin A-induced suppression of lymphoproliferation and TNF, lymphotoxin, gamma interferon, and IL-1 production in human leukocytes.Predictors of mucoid Pseudomonas colonization in cystic fibrosis patientsA murine model of chronic mucosal colonization by Pseudomonas aeruginosaDifferences in the binding specificities of Pseudomonas aeruginosa M35 and Escherichia coli C600 for lipid-linked oligosaccharides with lactose-related core regions.IL1B polymorphisms modulate cystic fibrosis lung disease.Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.IL-17A in human respiratory diseases: innate or adaptive immunity? Clinical implications.Inhaled aztreonam lysine: an evidence-based review.Staphylococcus aureus chronic and relapsing infections: Evidence of a role for persister cells: An investigation of persister cells, their formation and their role in S. aureus disease.Pseudomonas aeruginosa and Burkholderia cepacia infection in cystic fibrosis patients treated in Toronto and Copenhagen.Comparison of biophysical and biologic properties of alpha-helical enantiomeric antimicrobial peptides.The place of tobramycin in lower respiratory tract infections (LRTI).How mutant CFTR may contribute to Pseudomonas aeruginosa infection in cystic fibrosis.Neutrophil degranulation by Helicobacter pylori proteins.Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection.Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs.Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection.Cystic fibrosis in Saudi Arabia: common and rare presentations.Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis.Cystic fibrosis transmembrane conductance regulator (CFTR)-mediated residual chloride secretion does not protect against early chronic Pseudomonas aeruginosa infection in F508del homozygous cystic fibrosis patients.Macrolides in the respiratory tract in cystic fibrosis.
P2860
Q24561380-4DEF3651-8338-4B97-A9BF-EA30467791C3Q28319242-3DD9C185-0B5A-4BD6-90DF-2B1D60CE403EQ28492831-08BD1128-5E5B-4B37-A557-51318B8BF847Q30480308-B3A312E9-125C-4DC0-A1D0-0C3F6023EE78Q34073568-AA15C247-A1D6-4EB1-9D5F-5163CC457824Q34266590-5F6994F3-EA89-44EA-9E3E-9B4CCF1C6962Q34386327-E096C06D-BBF2-43FA-9898-8401E32C7274Q34481869-CA19777D-2F62-4174-A26F-8737BD8360FFQ34537794-9F367D20-0B45-446D-8E81-BBBAA0CDCE8FQ35534691-13B80778-EE92-4618-BA10-234BCDB4743AQ35913962-82B6F63C-7BCC-42BE-A638-C19044FD7A99Q35973303-FEFA8A49-48AA-4410-8FA0-80060B5F2E47Q36485158-08D4BB98-0973-414B-92B0-D0E8843C0FCCQ36520797-D8F92E43-56F5-4890-B110-6042EAE6709AQ36703983-D3C3E09D-9BD5-454D-A7A6-1588F7F3B4BBQ36949104-EDA15013-6A9D-476E-83D5-14FAD3535954Q36956804-A9FCACC4-1CAC-470D-BC07-2DE1E46C8CCEQ36971014-CAF0089F-9C2C-4DCB-85A6-AF8141512A9FQ36972478-0ECE8605-D1CF-4378-BD57-868C589332E9Q37027691-9E765644-ED0A-4074-8053-E2DD337522D4Q37470271-BF76FA05-D624-4C7E-92B5-CC040641C4E2Q38080843-5A7743CE-726B-47C4-B5D5-18D8E4092720Q38132897-57EAE03F-A48E-44DA-9849-6730223BD299Q38237595-1D8D2C5D-07BA-4166-AFB3-2D865B2CC639Q39474744-F272DCE6-7CFC-4156-A506-C8602A1261BEQ40190665-E4D580D2-02BD-4F2E-8C9A-732F753D767FQ40949894-5E4B300B-C8C7-401D-B0DF-29DD8CD2B661Q41163000-4C9DDED2-B1FE-4B46-934F-ACDB29AD812FQ41886175-1F034503-BD81-4310-A3B0-D75D82F7A3B8Q42011962-D33E4CD9-BDD0-4C2F-A68F-A24364BE6851Q42200170-29EFD7EF-20EA-4EF1-8822-3F737A6AD400Q42982215-DCD9C201-E5B2-4AA8-87D0-4358DD174980Q46324658-49521D5E-AEDE-4DFF-8ADC-F69215046DB3Q49147380-C0E7A216-44A1-4B03-BEF3-7E17282F84E4Q51644964-EADF92D7-13EF-4D95-AC3D-A908B0BAEEE7Q51704943-BD33D556-D909-4E40-8ECF-55E3907D800D
P2860
Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh
1990年學術文章
@zh-hant
name
Cystic fibrosis. 1. Pseudomona ...... ic fibrosis and its management
@en
type
label
Cystic fibrosis. 1. Pseudomona ...... ic fibrosis and its management
@en
prefLabel
Cystic fibrosis. 1. Pseudomona ...... ic fibrosis and its management
@en
P2860
P356
P1433
P1476
Cystic fibrosis. 1. Pseudomona ...... ic fibrosis and its management
@en
P2860
P304
P356
10.1136/THX.45.11.881
P407
P577
1990-11-01T00:00:00Z